Polypeptide With Localisation/Targeting Motif TRIZ Cases
- Bispecific Antibodies Targeting GPRC5D and CD3
GPRC5D-targeting bispecifics bridge myeloma cells and T-cells, resolving specificity gaps in existing therapies.
- miRNA Expression Construct Spacer Optimization
A miRNA expression construct uses a 50-nucleotide spacer to enhance DROSHA processing and mature miRNA production.
- Tandemly Repeated Antibody-Binding Protein for Immunoassay Sensitivity
Tandemly repeated antibody-binding proteins increase capture antibody loading on solid supports, resolving limited binding site availability in immunoassays.
- Engineered Thermostable Carbonic Anhydrase for Low-Energy CO2 Capture
Mutated carbonic anhydrases replace energy-intensive MEA scrubbing, enabling efficient CO2 capture with reduced thermal degradation.
- Cyclic Cell-Penetrating Peptide Conjugates for Intracellular Delivery
A cyclic cell-penetrating peptide conjugated with an endosomal escape vehicle enables intracellular delivery of antisense compounds.
- Protease Cleavable Bispecific Antibodies Tumor Activation
Segmented antibody structures with modified Fc regions extend half-lives while protease cleavage sites prevent lymphopenia.
- Humanized LAG-3 Animal Models for Accurate Immune Therapy Screening
Expressing human LAG-3 in animal models resolves species differences that cause high failure rates in traditional drug development pipelines.
- CAR Binding Sialyl Tn Glycan to Reduce Off-Target Toxicity
Chimeric antigen receptors target Sialyl Tn glycan to inhibit tumor growth while sparing normal tissues with low antigen expression.
- Virus-Like Nanoparticle Vaccine Using Spike Protein Display
Virus-like nanoparticles display SARS-CoV-2 spike protein domains to induce high-titer neutralizing antibody responses.
- Polypeptide Inhibitors Targeting Nuclear Speckle Association
A segmented polypeptide inhibitor disrupts transcription factor binding to nuclear speckles.
- SSEA4-Specific CAR T Cells for Ovarian Cancer Treatment
Genetically modified T cells use chimeric antigen receptors to target SSEA4, overcoming chemotherapy resistance in ovarian cancer.
- PDGFR-VEGFR Fusion Protein Decoy for Dual Pathway Inhibition
A PDGFR-VEGFR fusion protein acts as a decoy receptor to bind VEGF and PDGF simultaneously.
- Hypoxia-Regulated CAR-T Cells for CD138 Cancer Targeting
Engineered T cells express chimeric antigen receptors only in hypoxic tumor environments to target CD138-positive cancer cells.
- RSPO3-Binding Agents Inhibit Wnt Signaling for Cancer Therapy
RSPO3-binding agents inhibit tumor growth by blocking RSPO3-LGR interactions, reducing cancer stem cell frequency and angiogenesis.
- Fully Human TCRs Targeting hTERT Peptides via Class II MHC
Engineered fully human T-cell receptors redirect CD4 and CD8 T-cells to recognize hTERT peptides presented by Class II MHC molecules.
- Dual-Specific CAR T Cells for Solid Tumor Expansion
Segmenting the CAR into distinct antigen binding domains resolves the contradiction between long-term maintenance and solid tumor efficacy.
- Conditionally Active EpCAM Trispecific Protein Masking
Masked EpCAM trispecific proteins reduce off-target side effects by requiring tumor-associated protease cleavage for selective cancer cell targeting.
- MUC16 Antibodies Targeting Peptide Backbone for Cancer Detection
Antibodies target MUC16 peptide backbone to resolve low sensitivity and specificity limits in current cancer screening methods.